In mid-September, Novo Nordisk inked a pair of deals worth a total of more than $1.1 billion in research and development (R&D) costs, payments, milestone fees, and royalties, with the explicit aim of bolstering its cardiometabolic disease therapy pipeline via as-yet-unexplored therapeutic modalities.

Weight-loss drugs sell in Europe for a fraction of what they cost in the United States, a pattern that is typical for brand-name prescriptions.

The CEO of Novo Nordisk faced pointed questions about the cost of Ozempic and Wegovy on Capitol Hill Tuesday, as lawmakers pressed the Danish pharmaceutical giant to cut the prices of its blockbuster diabetes and obesity medications.

Novo Nordisk has a price fix solution for uninsured patients with diabetes, but not for HSA holders or people with normal blood sugar.

Novo Nordisk CEO Lars Fruergaard Jorgensen will testify Tuesday before a Senate panel looking into the drug maker's pricing of weight-loss drugs Wegovy and Ozempic.

For the millions of people living with diabetes or obesity, drugs like Ozempic and Wegovy can significantly improve their health.

Chairman of the Senate Committee on Health, Education, Labor, and Pensions (HELP), today led the committee in a hearing to examine why Novo Nordisk charges the American people the highest prices in the world for its lifesaving drugs,

During a tense hearing before a Senate committee on Tuesday, Novo Nordisk CEO Lars Fruergaard Jørgensen faced tough questions over the company's high prices for its blockbuster drugs Ozempic and Wegovy.